Claims

1. ~~Pidotimod~~ The use of pidotimod or its stereoisomers and/or physiologically acceptable salts thereof, ~~for use~~ in the manufacture of a medicament for the treatment of inflammation-associated diseases characterized by an aberrant hyperactivation of the non canonical NFkB pathway.
2. ~~Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for~~The use according to claim 1, characterized in that said diseases are allergic diseases, autoimmune diseases or inflammatory diseases based on mechanisms different from allergic and autoimmune.
3. ~~Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for~~The use according to claim 2, characterized in that said allergic diseases are selected from Allergic rhinitis, Allergic conjunctivitis, Atopic allergy, Atopic dermatitis, Contact dermatitis, Eczema and/or Allergic vasculitis.
4. ~~Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for~~ The use according to claim 2, characterized in that said autoimmune diseases are selected from Alopecia areata, Ankylosing Spondylitis, Autoimmune cardiomyopathy, Autoimmune connective tissue diseases, Autoimmune enteropathy, Autoimmune hepatitis, Autoimmune peripheral neuropathy, Autoimmune pancreatitis, Autoimmune polyendocrine syndrome, Autoimmune thrombocytopenic purpura, Autoimmune urticaria, Autoimmune uveitis, Celiac disease, Chronic Fatigue Syndrome, Cystic fibrosis, Hashimoto's thyroiditis, Idiopathic pulmonary fibrosis, Idiopathic thrombocytopenic purpura, IgA nephropathy, Juvenile idiopathic arthritis (or Juvenile rheumatoid arthritis, or Still's disease) Kawasaki's disease, Lichen planus, Lupus erythematosus, Rheumatoid arthritis, Rheumatic fever, Sjögren's syndrome, Spondyloarthropathy, Temporal arteritis (or giant cell arteritis), Ulcerative colitis, Urticarial vasculitis, Vitiligo.

5. ~~Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for~~The use according to claim 2, characterized in that said inflammatory diseases based on mechanisms different from allergic and autoimmune are selected from Alzheimer's disease, Atherosclerosis, Chronic Liver Diseases, Chronic Nephropathy, Gastritis, Glomerulonephritis, Hepatitis A B & C, Hydradenitis suppurativa, Hypogammaglobulinemia, Interstitial cystitis, Lichen sclerosus, Liver steatosis, Metabolic Syndrome, Obesity, Parkinson's disease, Pemphigus vulgaris, Post-ischemic inflammation, Psoriasis, Psoriatic arthritis, Raynaud phenomenon, Restless leg syndrome, Retroperitoneal fibrosis, Thrombocytopenia.
6. ~~Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for~~The use according to anyone of claims 1 to 5, characterized in that ~~it~~ the medicament is to be administered to a human.
7. ~~Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for~~The use according to any of claims 1 to 5, characterized in that ~~it~~ the medicament is to be administered systemically.
8. ~~Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for~~ The use according to claim 7, characterized in that ~~it~~ the medicament is to be administered by parenteral (intramuscular or intravenous) route or by enteral (oral or rectal) route.
9. ~~Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for~~ The use according to claim 7, characterized in that ~~it~~ the medicament is to be administered by means of a solid or liquid formulation.
10. ~~Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for~~ The use according to claim 9, characterized in that said solid formulation has a w/w concentration in pidotimod or a physiologically acceptable salt thereof from 50% to 90%, more preferably from 65% to 80%, most preferably from 70% to 75%.

11. ~~Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for~~ The use according to claim 9, characterized in that said liquid formulation has a w/w concentration in pidotimod or a physiologically acceptable salt thereof from 0.5% to 20%, more preferably from 1% to 10%, most preferably from 2% to 8%.
12. ~~Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for~~The use according to claim 9, characterized in that said solid formulation contains an amount of pidotimod or of a physiologically acceptable salt thereof, from 10 to 1000 mg per single dose, more preferably from 50 to 800 mg per single dose.
13. ~~Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for~~The use according to anyone of claims 1 to 5, characterized in that ~~it~~ the medicament is to be administered topically.
14. ~~Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for~~The use according to claim 13, characterized in that ~~it~~ the medicament is to be administered by dermal, ocular, auricular, nasal, buccal, ~~intrasinal~~ intranasal, endotracheal, vaginal, intravesical, or rectal route.
15. ~~Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for~~The use according to claim 13, characterized in that ~~it~~ the medicament is to be administered by means of a solid, semisolid or liquid formulation.
16. ~~Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for~~ The use according to claim 15, characterized in that said solid formulation has a w/w concentration in pidotimod or a physiologically acceptable salt thereof from 50% to 90%, more preferably from 65% to 80%, most preferably from 70% to 75%.
17. ~~Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for~~The use according to claim 15, characterized in that said semi-solid or liquid formulation has a w/w concentration in pidotimod or a

physiologically acceptable salt thereof from 0.1% to 30%, more preferably from 1% to 20%, most preferably from 5% to 15%.

18. ~~Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof for~~The use according to any of the preceding claims, characterized in that ~~it~~ the medicament is to be administered in combination or in temporal proximity with at least one additional active principle.